Boundless Bio reports Q1 2025 net loss $15.8M; $138.3M cash; BBI-355 data due H2 2025

Boundless Bio, Inc.

2025-Q1 EPS reported -$0.71

Cash, cash equivalents, and short-term investments totaled $138.3M as of March 31, 2025, providing runway into 2027.
Net loss of $15.8M for Q1 2025 versus $15.4M in Q1 2024; R&D expenses $12.1M ($13.1M Q1 2024), G&A $5.2M ($3.8M).
BBI-355 Phase 1/2 POTENTIATE trial enrollment ongoing; preliminary clinical proof-of-concept data expected second half 2025.
Novel Kinesin program: development candidate nomination expected mid-2025, IND filing planned for first half 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.